This page shows the latest CALD gene therapy news and features for those working in and with pharma, biotech and healthcare.
The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for bluebird bio’s Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD). ... Bluebird bio's Lenti-D (eli-cel/elivaldogene autotemcel) is a potential
Study shows continued benefit in treatment of rare disease. Last year, Bluebird Bio claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – it has now ... Lenti-D is Bluebird’s lead gene
News comes after impressive data from a phase II/III trial. Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare ... Bluebird’s gene therapy approach could do away
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... pipeline. This incudes Lenti-D, a gene therapy for patients with cerebral adrenoleukodystrophy (CALD), a rare,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...